Paper42657389
Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease.
Freidoon M and 8 others. J Res Med Sci, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease. Papers, record 42657389. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657389
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Association of Janus kinase 1 and 2 expression with clinical indices in diabetic kidney disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37635867 | JAK/STAT signaling in diabetic kidney disease. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/37635867 | PubMed |
| 2 | 34883189 | IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. | Diabetes Res Clin Pract | 2022 | https://conductscience.org/library/papers/34883189 | PubMed |
| 3 | 39924047 | Molecular mechanism and role of miRNA-155 ribonucleic acid in podocyte apoptosis in lupus nephritis: SOCS1 protein expression regulates JAK/STAT pathway transduction. | Int J Biol Macromol | 2025 | https://conductscience.org/library/papers/39924047 | PubMed |
| 4 | 19017763 | Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. | Diabetes | 2009 | https://conductscience.org/library/papers/19017763 | PubMed |
| 5 | 33901462 | JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. | Eur J Pharmacol | 2021 | https://conductscience.org/library/papers/33901462 | PubMed |
| 6 | 32471207 | Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32471207 | PubMed |
| 7 | 37936470 | Immunological Approaches in the Treatment of Diabetic Nephropathy. | Curr Diabetes Rev | 2024 | https://conductscience.org/library/papers/37936470 | PubMed |
| 8 | 34307650 | Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/34307650 | PubMed |
| 9 | 27333885 | JAK inhibition in the treatment of diabetic kidney disease. | Diabetologia | 2016 | https://conductscience.org/library/papers/27333885 | PubMed |
| 10 | 40155732 | MiR-203 improved renal cell injury in diabetic nephropathy by targeting SOCS6/SOCS7 and inhibiting JAK/STAT pathway activation. | Sci Rep | 2025 | https://conductscience.org/library/papers/40155732 | PubMed |
| 11 | 16527921 | Role of the JAK/STAT signaling pathway in diabetic nephropathy. | Am J Physiol Renal Physiol | 2006 | https://conductscience.org/library/papers/16527921 | PubMed |
| 12 | 39530557 | CD3D silencing alleviates diabetic nephropathy via inhibition of JAK/STAT pathway. | FASEB J | 2024 | https://conductscience.org/library/papers/39530557 | PubMed |
| 13 | 11168952 | Progression of diabetic nephropathy. | Kidney Int | 2001 | https://conductscience.org/library/papers/11168952 | PubMed |
| 14 | 34202668 | Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34202668 | PubMed |
| 15 | 34964875 | 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. | Diabetes Care | 2022 | https://conductscience.org/library/papers/34964875 | PubMed |
| 16 | 11967010 | Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. | Kidney Int | 2002 | https://conductscience.org/library/papers/11967010 | PubMed |
| 17 | 37625003 | Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. | Diabetes Care | 2023 | https://conductscience.org/library/papers/37625003 | PubMed |
| 18 | 18546601 | Analyzing real-time PCR data by the comparative C(T) method. | Nat Protoc | 2008 | https://conductscience.org/library/papers/18546601 | PubMed |
| 19 | 32061315 | Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. | Lancet | 2020 | https://conductscience.org/library/papers/32061315 | PubMed |
| 20 | 32267079 | An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. | Diabetes Obes Metab | 2020 | https://conductscience.org/library/papers/32267079 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| JAK1 | 3716 | PubTator's text mining | https://conductscience.org/library/genes/3716 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| JAK3 | 3718 | PubTator's text mining | https://conductscience.org/library/genes/3718 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42657389
GET https://conductscience.org/api/papers/v1/42657389/references?page=2